

05



DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Centers for Disease Control and Prevention
INTER/INTRA-AGENCY AGREEMENT (IAA)
Receivable Agreements (CDC is Performing Work)



1. CDC IAA # 10-17		2. PROCURING AGENCY IAA # CPSC-I-10-0000		3. TYPE OF AGREEMENT: <input checked="" type="checkbox"/> New <input type="checkbox"/> Modification <input type="checkbox"/> Administrative Modification Number	
4. TITLE OF PROJECT Exposure Assessment of Silver Nanoparticles in Treated Products				5. Type of Customer: <input checked="" type="checkbox"/> FED <input type="checkbox"/> Non-FED <input type="checkbox"/> Non-FED Billing	
6. DESCRIPTION OF WORK (Please attach) see attached		AMOUNT (Not to exceed without written modification) \$ 40,000.00			
7. NAME AND ADDRESS OF PROCURING AGENCY U.S. Consumer Product Safety Commission Office of Hazard Identification and Reduction 4330 East West Highway Bethesda, MD 20814 DUNS#069287522		Contact Name: <u>Trey A. Thomas, Ph.D.</u> Phone: <u>(301) 504-7738</u> Email: <u>thomas@cpsc.gov</u> Fax: <u>(301) 504-0079</u>			
8. NAME AND ADDRESS OF CDC CENTER, INSTITUTE, OR OFFICE NIOSH, Division of Respiratory Disease Studies 1095 Wilowdale Road Morgantown, WV 26505 DUNS#927645465		Contact Project Manager: <u>Aleks Stelaniak, Ph.D.</u> Phone: <u>(304) 285-</u> Email: <u>astelaniak@cdc.gov</u> Fax: <u>(304) 285 6321</u>			
9. PROJECT PERIOD From: <u>04/19/2010</u> Through: <u>12/31/2010</u>		BUDGET PERIOD From: <u>10/01/2009</u> Through: <u>09/30/2010</u>			
If agreement is longer than one year, the following statement applies and must be included in the agreement narrative: "This agreement is approved for Fiscal Year 20__ and may continue during Fiscal Year 20__ subject to availability of funds."					
10. AUTHORITY (CDC) <input type="checkbox"/> Economy Act approved June 30, 1932, as amended by 31 U.S.C. 1535 and 1536 (If detail of CDC personnel, justification is required.) <input checked="" type="checkbox"/> Other: (Please specify) <u>Public Health Service Act</u>					
11. AUTHORITY (Procuring Agency) <u>Sect 27(q) Consumer Prod Safety Act, (15 U.S.C. 2076(g))</u>		<input checked="" type="checkbox"/> CDC Standard Overhead (9% will be applied to all reimbursable agreements) <input checked="" type="checkbox"/> CDC Overhead Waiver granted and approved by FMO Branch Chief			
12. CDC FUNDING INFORMATION Treasury Symbol-Appropriation: <u>75100943</u> Budget Activity: <u>6611-RF-11.01</u> Owning Org. Admin. Code: <u>HCCHC (LRB)</u> Fund Value: <u>921.60 2010 1RAQ</u> Crossing Code: <u>2811</u>		CDC ALC: <u>75090421</u> CIC, EIN: <u>586051157</u>		FISCAL YEAR: <u>2010</u>	
		CAN #1:		Direct Costs:	\$ <u>36,897.00</u>
		CAN #2:		CIO Indirect:	\$ _____ %
		CAN #3:		CDC Indirect:	\$ <u>3,303.00</u> %
				Total:	\$ <u>40,000.00</u>
13. PROCURING AGENCY BILLING REQUIREMENTS Treasury Symbol-Appropriation: <u>81100100 (1 year funds)</u> A/C: <u>41300001</u> FIN: <u>1239 8762</u> DUNS #: <u>069287522</u>		Billing will be processed through the use of the Intra-Governmental Payment and Collection (IPAC) system Billing Frequency: <input type="checkbox"/> Monthly <input type="checkbox"/> Quarterly <input checked="" type="checkbox"/> Other: <u>Immediate</u>			
14. ADDITIONAL BILLING REQUIREMENTS OF THE PROCURING AGENCY (Required if needed for invoice payment) None					
15. PROCURING AGENCY BUDGET CONTACT Name: <u>Deborah Peoples Hodge</u> Phone: <u>(301) 504-7130</u> Email: _____ Fax: _____		CIO CONTACT: Name: <u>Heather Rogers</u> Phone: <u>(304) 285-6002</u> CDC FMO BUDGET CONTACT Name: <u>Tonya Jacques</u> Phone: <u>(304) 285-6173</u>			
16. OTHER REQUIREMENTS A. Travel under this agreement is subject to allowances authorized in accordance with Federal Travel Regulations, Joint Federal Travel Regulations, and/or Foreign Service Regulations. B. Unless otherwise requested by the procuring agency, CDC will retain title to any equipment procured in order to provide service.					
17. CDC ACCEPTANCE (Please print) Name: <u>Kelley Durst</u> Title: <u>Assoc Director for Planning and Performance, NIOSH</u> Email Address: <u>kdurst@cdc.gov</u> Signature: <u>Kelley Durst</u> Date: <u>3/29/10</u>			18. PROCURING AGENCY ACCEPTANCE (Please print) Name: <u>Donna Hutton</u> Title: <u>Director, Division of Procurement Services, CPSC</u> Email Address: <u>dhutton@cpsc</u> Signature: <u>Donna Hutton</u> Date: <u>4/10/10</u>		

CPSC-1-10-0006
INTERAGENCY AGREEMENT (IAG)
BETWEEN THE
U.S. CONSUMER PRODUCT SAFETY COMMISSION
AND THE
CENTERS FOR DISEASE CONTROL AND PREVENTION
NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH

I. INTRODUCTION

The U.S. Consumer Product Safety Commission, hereinafter referred to as CPSC, and the Centers for Disease Control and Prevention, National Institutes for Occupational Safety and Health, hereinafter referred to as NIOSH, hereby agree the NIOSH, subject to the terms and conditions herein, shall develop appropriate analytical methods for determining if silver nanoparticles are released from products, and quantify any releases of silver nanoparticles from treated products.

II. TITLE

Exposure Assessment of Silver Nanoparticles in Treated Products

III. BACKGROUND

The unique properties of nanosilver are being exploited for use in consumer products, including room sprays, laundry detergents, and wall paint; textiles, including shirts, pants, and underwear, and products intended for use by children such as baby bottles, teething rings, and plush toys. Health effects associated with silver vary with the chemical form (metallic, salt) and the route of exposure (ingestion, inhalation, and dermal contact). Understanding and, where necessary, reducing, potential exposures to consumers from use of nanosilver-enabled products is critical for promoting public health; however, the mechanisms and forms of silver released from products containing nanosilver are poorly understood.

Available studies on nanosilver indicate exposure potential from some nanosilver-enabled textiles; however, the methodologies used were poorly described and results obtained were highly variable precluding generalization of these studies to other consumer products. In the proposed study, scientifically credible protocols will be used to evaluate exposure potential to nanosilver from consumer products.

The major output of this project will be increased understanding of exposure potential from use of nanosilver-enabled products by the public and workers, which is an area of high mutual interest to both the CPSC and the NIOSH. Results of this study will provide a foundation for future work to evaluate levels of exposure to nanosilver from consumer products and materials found in occupational settings via relevant pathways.

IV. PURPOSE AND OBJECTIVES

The purpose of this study is to use scientifically credible protocols to evaluate exposure potential to nanosilver from treated products. The NIOSH will test the broad hypothesis that nanosilver is released from products under conditions of intended use.

V. STATEMENT OF WORK

The project aims are:

1. Identify products from four categories of goods that claim to contain nanosilver;
2. Determine whether the material in the consumer product is nanosilver;
3. Determine the form of silver released from products under conditions of intended use;
4. Identify pathways of exposure potential (ingestion, dermal, and/or inhalation routes) from use of these products.

NIOSH will:

1. Identify two or more products from four major categories (textiles, cleaners, kitchenware, other products) of goods that claim to contain nanosilver;
2. Determine whether the material in the product is nanosilver;
3. Determine the form of silver (soluble, metallic) that is released from the product under conditions of intended use- nanoform or large agglomerates; and
4. Identify pathways of exposure potential (ingestion, dermal, and/or inhalation routes) from use of these products.

Available databases will be used to identify potential products for study, and develop a focused list of products for evaluation (specific aim #1). For those particles that contain nanosilver, the chemical form (Ag^0 , Ag^+) and physicochemical properties (morphology, size, chemistry) of material released from the products during simulated use activities will be evaluated using appropriate analytical techniques (specific aim #3). Finally, for those products that release nanosilver, pathways of exposure will be identified (specific aim #4).

Products of this research will include information applicable to the CPSC, NIOSH, other Federal agencies (e.g. EPA), and the broader environmental health and safety (EHS) community.

1. scientifically-credible protocols for evaluating engineered nanomaterial release from consumer products;
2. a framework for developing exposure pathway analyses for nano-enabled consumer products; and
3. development of a better understanding of pertinent human exposure factors for potential nanomaterial-induced health outcomes in the non-occupational and occupational environments.

VI. NIOSH FURNISHED MATERIALS/EQUIPMENT

NIOSH agrees to furnish all necessary personnel, equipment, materials, services, and facilities to complete the objective listed in Section V.

Travel under this agreement is subject to allowances authorized in accordance with Federal Travel Regulations, Joint Federal Travel Regulations, and/or Foreign Service Regulations.

Unless otherwise requested by the procuring agency, CDC will retain title to any equipment procured in order to provide service.

VII. NONDISCLOSURE OF DATA

The Contractor agrees that it and its employees will not disclose any data obtained or developed under this contract to third parties without the consent of the U. S. Consumer Product Safety Commission Contracting Officer.

VIII. REPORTING REQUIREMENTS

NIOSH will provide preliminary test reports documenting the test protocols and resulting data at the completion of each task. Within 60 days of completion of the testing, NIOSH will issue a draft final report for CPSC staff review. Following CPSC staff review, NIOSH will have an additional 30 days to deliver the final report summarizing the test data.

DELIVERY ITEM	QUANTITY	PERFORMANCE
A. All recorded test data and findings	2 copies	Within 7 days of completion
B. Representative photographs	2 copies	Within 7 days of completion

IX. PERIOD OF PERFORMANCE

The period of performance shall begin on the effective date and shall not extend beyond December 31, 2010. This agreement may be modified or cancelled by mutual consent of CPSC and NIOSH.

X. DELIVERY OR PERFORMANCE

All deliverables required under the terms and conditions of this IAG shall be provided to the CPSC. The activities planned under this agreement are expressly subject to the availability of funds and other necessary resources to the parties. The following items shall be performed or delivered in accordance with the following schedule.

Month 1 - Obtain materials for this study.

Month 3- Complete sample preparation and method development

Month 6 - Report quantity of silver nanoparticles released from treated materials.

Month 9 - Submit final report

The period of performance for this agreement is from the date of signature by both parties through December 31, 2010.

XI. DISAGREEMENTS

In the event that the CPSC and NIOSH have a disagreement arising under this Interagency Agreement, then the parties shall cooperatively seek to resolve the disagreement by themselves. If the disagreement cannot be resolved between them, then the parties agree to seek the assistance of a third party in resolving the disagreement.

XII. LIAISON OFFICERS

- a. NIOSH PROJECT OFFICER
Aleks Stefaniak, Ph.D.
Research Industrial Hygienist
NIOSH/DRDS/LRB
1095 Willowdale Road, MS 4020
Morgantown, WV 26505
Phone: 304-285-6302
Fax: 304-285-6321
astefaniak@cdc.gov

h. CDC/NIOSH FMO BUDGET ANALYST

Tonya Jacquez
Budget Analyst
CDC/OD/OCCO/FMO
1095 Willowdale Road, MS 4020
Morgantown, WV 26505
Phone: 304-285-6173
Fax: 304-285-6126

a. CPSC PROJECT OFFICER
Treye A. Thomas, Ph.D.
U.S. Consumer Product Safety Commission
Office of Hazard Identification and Reduction
4330 East West Highway,
Bethesda, MD 20814
Phone: (301) 504-7738
tthomas@cpsc.gov

b. CPSC FINANCIAL OFFICER
Ms. Deborah Peebles Hodge
U.S. Consumer Product Safety Commission
4330 East West Highway,
Bethesda, MD 20814
Phone: (301) 504-7130

XIII. COST AND TRANSFER OF FUNDS

CPSC will provide \$40,000 in FY 2010 to support the activities described in this agreement.

XIV. FUNDING AND ACCOUNTING DATA

The transfer of funds shall be from CPSC to NIOSH through the On-Line Payment Collection (OPAC) system using the following accounting data:

Transfer From:

CPSC

Taxpayer ID Number (TIN): 520978750

Agency Location Code (ALC): 61000061

DUNS 069287522

US Treasury Code: ~~60200000~~61-0100

AMOUNT: \$ 40,000.00

**ACCT. & APPROP. DATA: 0100A10DPS 2010 2370400000
EXHR004000 253I0**

To:
NIOSH
Taxpayer ID Number (TIN): 586051157
Agency Location Code (ALC): 75090421
DUNS: 927645465
US Treasury Code: 75-10-0943


XV. AUTHORITIES

FOR CPSC:
Section 27(g) of the Consumer Product Safety Act. (15 U.S.C. 2076(g))

FOR NIOSH
The Public Health Service Act.


Approved and Accepted for CDC/NIOSH:

BY: _____


Kelley Durst
Associate Director for Planning and Performance
National Institute for Occupational Safety and Health
2400 Century Parkway NE (4th Floor)
Atlanta, GA 30345
Phone: (404) 498-2500
Fax: (404) 498-2573

Approved and Accepted for CPSC

BY: _____


Donna Hutton
Director, Division of Procurement Services
U.S. Consumer Product Safety Commission
4330 East West Highway
Bethesda, MD 20814
Phone: (301) 504-7009
Fax: (301) 504-0628

4/8/10